Therefore, ixazomib is a potential drug for the treatment of DHL-BCL2, and its combination with CHK2 inhibitors provides a potential treatment option for drug-resistant DLBCL and DHL-BCL2 [337]. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.